FIXX - Homology Medicines, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.60
+0.09 (+0.46%)
At close: 4:00PM EDT

19.60 0.00 (0.00%)
After hours: 5:20PM EDT

Stock chart is not supported by your current browser
Previous Close19.51
Open19.56
Bid18.00 x 1000
Ask25.16 x 900
Day's Range19.00 - 19.61
52 Week Range15.07 - 31.80
Volume109,024
Avg. Volume260,279
Market Cap871.167M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.25
Trade prices are not sourced from all markets
  • GlobeNewswire2 hours ago

    Homology Medicines Appoints Alise Reicin, M.D., to the Board of Directors

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that Alise Reicin, M.D., has been appointed to its Board of Directors. Dr. Reicin is the President, Global Clinical Development at Celgene Corporation where she is responsible for mid- to late-stage clinical development across Celgene’s portfolio and is a member of the company’s Executive Committee.

  • GlobeNewswire18 days ago

    Homology Medicines Announces Leadership Updates

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today changes to its leadership team, which positions the Company for continued growth as a clinical-stage company. Sam Rasty, Ph.D., is stepping down as Chief Operating Officer to assume the role of President and Chief Executive Officer of Platelet BioGenesis, an early stage biotechnology company. In conjunction with Dr. Rasty’s departure, Brad Smith, Chief Financial Officer, who also manages Homology’s information technology, facilities and intellectual property portfolio, will assume responsibility for corporate development.

  • Could The Homology Medicines, Inc. (NASDAQ:FIXX) Ownership Structure Tell Us Something Useful?
    Simply Wall St.20 days ago

    Could The Homology Medicines, Inc. (NASDAQ:FIXX) Ownership Structure Tell Us Something Useful?

    The big shareholder groups in Homology Medicines, Inc. (NASDAQ:FIXX) have power over the company. Large companies...

  • GlobeNewswire28 days ago

    Homology Medicines Presents Data Showing Single Dose HMI-102 Resulted in Long-Term Correction of PKU, Including Reduction of Phe and Increased Brain Neurotransmitters in Murine Model

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the presentation of data highlighting the ability of a single administration of HMI-102, the Company’s lead AAVHSC15 gene therapy candidate for the treatment of phenylketonuria (PKU) in adults, to achieve long-term correction of PKU in PAHenu2 mice on a normal diet. PKU is an inborn error of metabolism caused by a mutation in the PAH gene that results in a potentially toxic buildup of phenylalanine (Phe), an essential amino acid derived primarily from dietary protein.

  • GlobeNewswirelast month

    Homology Medicines to Present at JMP Securities Life Sciences Conference

    BEDFORD, Mass., June 13, 2019 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the JMP.

  • GlobeNewswirelast month

    Homology Medicines Initiates Phase 1/2 Study for HMI-102 Gene Therapy Candidate for Adults with PKU and Expects Initial Clinical Results by Year End 2019

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that it has commenced enrollment of the Phase 1/2 pheNIX trial for HMI-102, a one-time gene therapy development candidate for the treatment of adults with phenylketonuria (PKU). The pheNIX study is designed to evaluate the safety and efficacy of the investigational gene therapy in a randomized, concurrently-controlled, dose-escalation study. PKU is an inborn error of metabolism caused by a mutation in the PAH gene that results in a potentially toxic buildup of phenylalanine (Phe), an essential amino acid derived primarily from dietary protein.

  • GlobeNewswire2 months ago

    Homology Medicines Announces FDA Fast Track Designation for HMI-102 Gene Therapy Development Candidate for Adults with PKU

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for HMI-102, Homology’s one-time gene therapy development candidate for the treatment of adults with phenylketonuria (PKU). PKU is an inborn error of metabolism primarily caused by mutations in the PAH gene that lead to phenylalanine hydroxylase (PAH) deficiency resulting in the inability to breakdown phenylalanine (Phe), an essential amino acid found in natural protein.

  • Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates

    Homology Medicines (FIXX) delivered earnings and revenue surprises of -16.36% and -73.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Homology Medicines: 1Q Earnings Snapshot

    On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 64 cents. The gene editing company posted revenue of $270,000 in the period. Homology Medicines shares have decreased ...

  • GlobeNewswire2 months ago

    Homology Medicines Reports First Quarter 2019 Financial Results and Recent Highlights

    - Received FDA Clearance for IND and Anticipate Starting Phase 1/2 pheNIX Trial for PKU Gene Therapy Candidate with Initial Data Expected by Year End - - Began IND-Enabling.

  • Is Homology Medicines, Inc. (FIXX) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is Homology Medicines, Inc. (FIXX) A Good Stock To Buy?

    At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]

  • GlobeNewswire2 months ago

    Homology Medicines to Present at Bank of America Merrill Lynch Health Care Conference

    BEDFORD, Mass., May 09, 2019 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate during a fireside.

  • Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks2 months ago

    Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Homology Medicines Presents Data from Gene Therapy and Gene Editing Programs and Manufacturing Capabilities at ASGCT Meeting

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the presentation of data highlighting its gene therapy and gene editing platform and manufacturing capabilities at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). New data presented at ASGCT showed that Homology’s Manufacturing Platform, including serum-free suspension transfection, is scalable and an optimized approach to manufacture Homology’s novel adeno-associated virus vectors (AAVHSCs), resulting in superior in vitro infectivity and in vivo efficacy compared to a baculovirus process.

  • GlobeNewswire2 months ago

    Homology Medicines Presents Data Demonstrating Suite of Novel AAV Vectors Targeted Key Cell Types for Inherited Retinal Diseases

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the presentation of preclinical data demonstrating that, with a single dose, the Company’s suite of novel adeno-associated virus vectors targeted cell types frequently associated with inherited retinal diseases. The presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting showed that Homology’s vectors, which are derived from human hematopoietic stem cells (AAVHSCs), were able to target and enter (transduce) therapeutically relevant cells in the eye in three models using multiple routes of administration, including intravenous, intravitreal and subretinal injections.

  • GlobeNewswire3 months ago

    Homology Medicines Announces Upcoming Presentations on its Gene Therapy and Gene Editing Platform and Manufacturing Capabilities at the American Society of Gene & Cell Therapy Meeting

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today upcoming presentations highlighting its gene therapy and gene editing platform, including its phenylketonuria (PKU) and metachromatic leukodystrophy (MLD) programs, as well as its manufacturing capabilities. “The broad applicability of our dual gene therapy and gene editing platform is evident in the abstracts accepted for oral and poster presentations at ASGCT, and we believe they show the progress we have made in advancing our programs and technology platform to develop new and potentially curative treatment options for patients,” said Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines.

  • GlobeNewswire3 months ago

    Homology Medicines Announces Pricing of Public Offering of Common Stock

    Homology Medicines, Inc. (FIXX), a genetic medicines company, today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock, at a public offering price of $22.50 per share, before underwriting discounts and commissions. Homology also granted the underwriters a 30-day option to purchase up to an additional 833,333 shares of its common stock. All of the shares in the offering are to be sold by Homology.

  • GlobeNewswire3 months ago

    Homology Medicines Announces Proposed Public Offering of Common Stock

    Homology Medicines, Inc. (FIXX), a genetic medicines company, today announced that it intends to offer and sell, subject to market and other conditions, $125.0 million of its common stock in an underwritten public offering. Homology expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of its common stock. All of the shares in the proposed offering are to be sold by Homology.

  • GlobeNewswire3 months ago

    Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today preclinical data demonstrating that HMI-102, its gene therapy candidate for the treatment of phenylketonuria (PKU), restored the normal phenylalanine metabolic pathway as evidenced by measurements of key biomarkers in the disease model. The presentation at the ACMG Annual Clinical Genetics Meeting demonstrated long-term durability of the one-time administration of HMI-102 in reducing serum phenylalanine (Phe) and increasing tyrosine levels, due to an increase in phenylalanine hydroxylase (PAH) enzyme activity. “As we prepare to start our Phase 1/2 clinical trial with HMI-102 for adults with PKU, we are pleased to share further evidence that our one-time gene therapy candidate has restored the normal biochemical pathway that is lost in PKU,” stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines.

  • GlobeNewswire3 months ago

    Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (FDA) has provided clearance for Homology to begin its Phase 1/2 pheNIX clinical trial with HMI-102, a one-time gene therapy candidate for adults with the rare genetic disease phenylketonuria (PKU), an inborn error of metabolism. Homology has been working closely with multiple clinical sites in the U.S. to prepare for potential initiation of the pheNIX trial, which is designed to evaluate the safety and efficacy of the investigational gene therapy in a randomized, concurrently-controlled, dose-escalation study in adult patients with classic PKU.

  • Can You Imagine How Homology Medicines's (NASDAQ:FIXX) Shareholders Feel About The 77% Share Price Increase?
    Simply Wall St.3 months ago

    Can You Imagine How Homology Medicines's (NASDAQ:FIXX) Shareholders Feel About The 77% Share Price Increase?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you c...

  • GlobeNewswire4 months ago

    Homology Medicines to Present at the Alliance for Regenerative Medicine Investor Day

    BEDFORD, Mass., March 19, 2019 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present during a fireside.

  • Associated Press4 months ago

    Homology Medicines: 4Q Earnings Snapshot

    The Bedford, Massachusetts-based company said it had a loss of 51 cents per share. The gene editing company posted revenue of $980,000 in the period. For the year, the company reported a loss of $57.2 ...

  • GlobeNewswire4 months ago

    Homology Medicines Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Recent Accomplishments

    - On Track to Enter the Clinic and Report Initial Data from Phase 1/2 PKU Gene Therapy Trial in 2019 - - New Data Supporting HMI-102 IND Package Demonstrates Reduction of Phe.

  • GlobeNewswire4 months ago

    Homology Medicines to Present at Cowen Healthcare Conference

    BEDFORD, Mass., March 06, 2019 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the Cowen and.